<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477371</url>
  </required_header>
  <id_info>
    <org_study_id>S-20130050</org_study_id>
    <nct_id>NCT02477371</nct_id>
  </id_info>
  <brief_title>Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial</brief_title>
  <acronym>FARGO</acronym>
  <official_title>Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FARGO trial is a prospective, randomized (1:1), multicenter study. The aim of the study
      is to assess the importance of fractional flow reserve (FFR) assessment prior to coronary
      artery bypass grafting (CABG) with respect to planning and guiding the revascularization
      strategy. The study compares an FFR-guided strategy to an angiography-guided strategy in
      patients planned for surgical revascularization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FFR measurements are made on all patients that enters the study. FFR measurements on coronary
      arteries with intermediate stenoses, that are planned for grafting, are done before CABG is
      performed. Patients are randomized to either an FFR-guided CABG or an Angiography guided
      CABG.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage open grafts of all grafts</measure>
    <time_frame>6 months</time_frame>
    <description>Open graft definition: graft with TIMI III flow with no anastomosis stenosis (TIMI flow grades based on results of the Thrombolysis In Myocardial Infarction trial)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft stenosis (shaft and anastomoses)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CCS class from index to follow-up (FU)</measure>
    <time_frame>6 months</time_frame>
    <description>CCS class (Canadian Cardiovascular Society grading of angina)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life (EQ-5D) from index to FU</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE (Major Adverse Cardiac and Cerebrovascular event: death, myocardial infarction, stroke, new revascularization by CABG or PCI (Percutaneous coronary intervention)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural maximum Troponin I (cTnI), Troponin T (TnT) or creatinine kinase MB (CKMB) values depending on local conditions.</measure>
    <time_frame>The first 24 hours after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>During surgery (minutes)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Fractional flow reserve-guided CABG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to an FFR-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan form the heart team meeting are changed by the study investigator according to the FFR-measurements and randomization, so that coronary arteries with FFR ≤ 0,8 receive grafting and coronary arteries with FFR &gt; 0,8 are deferred.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-guided CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to an angiography-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan are based on the coronary angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fractional flow reserve-guided CABG</intervention_name>
    <description>Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values &gt; 0,8 are deferred.</description>
    <arm_group_label>Fractional flow reserve-guided CABG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiography-guided CABG</intervention_name>
    <description>Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.</description>
    <arm_group_label>Angiography-guided CABG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable angina or unstable angina / NSTEMI (Non ST segment elevation myocardial
             infarction) candidate to CABG

          -  At least one study lesion, which is an intermediate lesion planned for grafting at the
             Heart Team Meeting.(Definition of Study lesions: ≥ 50% stenosis of a major epicardiel
             artery (where the proximal reference segment has a diameter&gt; 2.5 mm), which can be
             passed with a FFR-wire without significant risk. Study Lesions can be drawn from all
             coronary arteries.)

          -  Signed informed consent form

        Exclusion Criteria:

          -  Significant valvular disease with indication to surgical treatment

          -  Previous open-heart-surgery

          -  Left main lesion without other intermediate lesions

          -  Treatment with Persantin Retard

          -  One vessel disease

          -  Renal impairment (creatinine ≥ 150 umol / l)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Langhoff Thuesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardio-thoracic surgery, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisette Okkels Jensen, MD,PhD,DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Thayssen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Poul Erik Mortensen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardio-thoracic surgery, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Langhoff Thuesen, MD</last_name>
    <phone>004526392012</phone>
    <email>anne@thuesen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology and Cardiothoracic surgery, Aarhus University Hospital, Skejby Sygehus</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evald Høj Christiansen, MD, PhD</last_name>
      <email>evald.christiansen@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Evald Høj Christiansen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Langhoff Thuesen</name>
      <address>
        <city>Odense</city>
        <state>Odense C</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Langhoff Thuesen, MD</last_name>
      <email>anne@thuesen.com</email>
    </contact>
    <investigator>
      <last_name>Anne Langhoff Thuesen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisette Okkels Jensen, MD,PhD,DMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per Thayssen, MD, DMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Poul Erik Mortensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology and Cardiothoracic surgery, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Svend Eggert Jensen, MD, PhD</last_name>
      <email>svend.eggert.jensen@rn.dk</email>
    </contact>
    <investigator>
      <last_name>Svend Eggert Jensen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Anne Langhoff Thuesen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

